🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07304908
Active, not recruiting Not applicable

Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine

NCT07304908 · tracked via the Priya Life Science China tracker
Sponsor
Peking University
Phase
Not applicable
Started
2025-11-25
Last updated
2025-12-26

Condition(s) studied

Large Language ModelsAcceptability of Health CarePerception, Self

Investigational drug(s) / intervention(s)

Perception-based interventions

Perception-based interventions: Participants allocated to the intervention group received perception-based interventions. Interventions for Groups 1-3 were perceived benefits of LLMs in medicine, perceived racial bias in LLMs in medicine, and perceived ethical conflicts in LLMs in medicine, respectively.

Study summary

Large language models (LLMs) show promise in medicine, but concerns about their accuracy, coherence, transparency, and ethics remain. To date, public perceptions on using LLMs in medicine and whether they play a role in the acceptability of health care applications of LLMs are not yet fully understood. This study aims to investigate public perceptions on using LLMs in medicine and if interventions for perceptions affect the acceptability of health care applications of LLMs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * ≥18 years * Capable of completing an online survey * Agree to sign an informed consent form Exclusion Criteria: * Unable to answer questions or communicate * Not willing to participate in this study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jue Liu Beijing Beijing Municipality

More Peking University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07304908 on ClinicalTrials.gov ↗ ← All trials in China